Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifei Xiaoji Wan in advanced NSCLC
NCT06406166Recruiting
- Sponsor
- Henan University of Chinese Medicine
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- NPI (Non-Pharmacological Intervention), Herbal Formulation
- Countries
- 1
01
Overview
Randomised, open-label trial of Lifei Xiaoji Pill in non-small cell lung cancer (NSCLC), sponsored by Henan University of Chinese Medicine. Primary endpoints: Overall Survival at 1 year and Progression-Free Survival at 1 year. Started Jun 2022; status: recruiting.
02
Drugs
Lifei Xiaoji Pill
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06406166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06406166.